[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100197253":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":25,"locations":33,"responsibleParty":46,"collaborators":50,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":78,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exendin 9,39","EXPERIMENTAL","Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol\u002Fkg\u002Fmin for 360 minutes.",[13],"Drug: Exendin 9,39",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Subjects randomized to this arm will receive a saline infusion for 360 minutes.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Exendin 9,39 is a competitive antagonist of endogenous GLP-1.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"A saline infusion will be given to match the study drug infusion.",[15],[30],{"name":31,"affiliation":5,"role":32},"Adrian Vella, M.D.","PRINCIPAL_INVESTIGATOR",[34],{"facility":5,"status":25,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":25},"Rochester","Minnesota","55905-0001","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-92.4699,44.02163,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Adrian Vella","Consultant, Endocrinology",[51,54],{"name":52,"class":53},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"name":55,"class":53},"National Center for Research Resources (NCRR)","100197253","early-phase-1-the-contribution-of-incretin-hormones-to-the-amelioration-of-glucose-metabolism-after-roux-en-y-gastric-bypass-100197253",false,"NCT01843855","The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass","Inclusion Criteria:\n\n* Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of \\> 110 mg\u002FdL\n* Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).\n\nExclusion Criteria:\n\n* Subjects taking thiazolidinediones\n* Subjects with active systemic illness\n* Subjects with active microvascular or macrovascular complications of their diabetes\n* For female subject: positive pregnancy test at the time of enrollment in study","ALL","20 Years","65 Years",{"count":66,"type":67},12,"ACTUAL","INTERVENTIONAL",[70],"EARLY_PHASE1","The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.",[73],"Type 2 Diabetes Mellitus",[75,76,77],"Gastric Bypass","bariatric surgery","glucose metabolism","COMPLETED","2013-12-03",{"date":81,"type":82},"2013-12-04","ESTIMATED",{"date":84,"type":25},"2011-06",{"date":86,"type":67},"2013-09",{"name":48,"class":6},1]